Results 61 to 70 of about 146,874 (392)

A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer

Case Reports in Ophthalmology, 2022
Trastuzumab is the cornerstone treatment for HER2-positive breast cancer. While ocular side effects are more commonly described after the use of the antibody-drug conjugate ado-trastuzumab emtansine, we here describe corneal melting in a 79-year-old ...
Deborah Peeters, Melissa Vereecken, Hannelore Denys, Dimitri Roels   +3 more
doaj   +1 more source

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]

, 2014
The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Bown, James L., Deeni, Yusuf Y., Goltsov, Alexey, Harrison, David J., Hu, Huizhong, Khalil, Hilal S., Kyriakidis, Stylianos, Langdon, Simon P., Soininen, Tero   +8 more
core   +6 more sources

Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

Cancers, 2021
Simple Summary Overexpression of HER2 receptors have been identified in various types of cancer including breast cancer and ovarian cancer. HER2 overexpression is generally associated with poor clinical outcomes in patients with HER2-positve tumors ...
H. Maadi, Mohammad Hasan Soheilifar, Won-Shik Choi, Abdolvahab Moshtaghian, Zhixiang Wang   +4 more
semanticscholar   +1 more source

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. [PDF]

, 2013
Data characterizing demographics, treatment patterns, and clinical outcomes in black patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited.
Abidoye, Oyewale O, Brufsky, Adam M, Kaufman, Peter A, Mayer, Musa, Rugo, Hope S, Tripathy, Debu, Ulcickas Yood, Marianne, Yardley, Denise A, Yoo, Bongin   +8 more
core   +1 more source

Immune Effects of Trastuzumab

Journal of Cancer, 2011
Trastuzumab's targeted therapy has become a stronghold for human epidermal growth factor receptor 2 positive breast cancer patients. This humanized monoclonal antibody binds to the extracellular juxta-membrane domain of HER2 and inhibits the proliferation and survival of HER2 dependent cancer cells.
NUTI, Marianna, BELLATI, FILIPPO, VISCONTI, Valeria, NAPOLETANO, Chiara, DOMENICI, LAVINIA, CACCETTA, JLENIA, ZIZZARI, ILARIA GRAZIA, RUSCITO, ILARY, RAHIMI KOSHKAKI, HASSAN, BENEDETTI PANICI, PIERLUIGI, RUGHETTI, Aurelia   +10 more
openaire   +3 more sources

Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing

Frontiers in Pharmacology, 2021
Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies. However, IFNs have a short in vivo half-life, systemic toxicity, and poor biophysical properties, which prevent it from being widely used for cancer therapy ...
Chan Gyu Lee, Chan Gyu Lee, TaeEun Kim, Sungyoul Hong, Jongwan Chu, Ju Eun Kang, Hee Geon Park, Jun Young Choi, Kyoung Song, Sun Young Rha, Soohyeon Lee, Joon-Seok Choi, Sun Min Kim, Hae Min Jeong, Young Kee Shin, Young Kee Shin, Young Kee Shin, Young Kee Shin   +17 more
doaj   +1 more source

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

New England Journal of Medicine, 2019
BACKGROUND Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral,
R. Murthy, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S. Hurvitz, N. Lin, V. Borges, V. Abramson, C. Anders, P. Bedard, Mafalda Oliveira, E. Jakobsen, T. Bachelot, S. S. Shachar, V. Müller, S. Braga, F. Duhoux, R. Greil, D. Cameron, L. Carey, G. Curigliano, K. Gelmon, G. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, M. C. Palanca-Wessels, L. Walker, W. Feng, E. Winer   +31 more
semanticscholar   +1 more source

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics

Journal of Ovarian Research, 2010
Background Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and
Wilken Jason A, Webster Kristy T, Maihle Nita J   +2 more
doaj   +1 more source

Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition

Biomedicines, 2022
Trastuzumab, a HER2-targeted antibody, is widely used for targeted therapy of HER2-positive breast cancer (BC) patients; yet, not all of them respond to this treatment.
Dmitrii Kamashev, Nina Shaban, Maria Suntsova, Mikhail Raevskiy, Victor Efimov, Aleksey Moisseev, Maxim Sorokin, Anton Buzdin   +7 more
doaj   +1 more source

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

Proceedings of the National Academy of Sciences of the United States of America, 2021
Significance This study demonstrates the efficacy of combining macrophage-checkpoint inhibition with tumor-specific antibodies for cancer immunotherapy.
Rosalynd Upton, A. Banuelos, D. Feng, Tanuka Biswas, Kevin S. Kao, K. McKenna, S. Willingham, P. Ho, B. Rosental, M. C. Tal, T. Raveh, J. Volkmer, M. Pegram, I. Weissman   +13 more
semanticscholar   +1 more source